Drug resistance is increasing among a variety of human pathogenic microorganisms such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumaniii, Pseudomonas aeruginosa and Enterobacter spp. (currently dubbed the 'ESKAPE' pathogens), and has emerged as one of the most important clinical challenges of this century. Increased general awareness and fear of these pathogens means there is a growing demand for research to tackle the threat of multidrug resistance. Documenting the latest research in the field, this book discusses current and promising activities to discover new antimicrobials in five key areas: molecular genetics and systems microbiology; synthetic, computational chemistry and chemoinformatics; High Throughput Screening (HTS); non-vertebrate model hosts; and light- and nano-based technologies.

Tuberculosis is a global health threat and the unique features of Mycobacterium tuberculosis and emergence of drug-resistant strains highlight the challenge it presents. Covering a wealth of state-of-the-art knowledge from active international experts, this book captures the latest developments in the advent of bacteriological, immunological and molecular tools for diagnosis and the development of new drugs. It shows how the challenge of tuberculosis is currently being met, providing insight into the evidence base underlying new developments in diagnosis, drug development and treatment.